ClinicalTrials.gg
CompletedNCT03605277Updated Oct 12, 2021

Pharmacokinetics Study of Asciminib in Subjects With Impaired Renal Function Compared to Matched Healthy Volunteers

A Phase 1 interventional study of Asciminib in Renal Impairment, sponsored by Novartis Pharmaceuticals. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-12.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 37 studies in Renal Insufficiency by Novartis — 1 open to participants now, 2 under way, none of them phase 3. Renal Insufficiency · Novartis.

Enrollment
33rd of 36
14 · median 37
Started
2018
the only one that year
Phase 1
21 of 37
1 open now
Registered
33rd of 37
by date

Among the 37 studies in Renal Insufficiency by Novartis, this one is the 33rd largest by enrollment of the 36 interventional ones that give a count, is the only one that started in 2018, is one of 21 in phase 1, and was the 33rd registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 145 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

1 of the 37 studies in Renal Insufficiency by Novartis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 91 Renal Insufficiency studies recruiting now, 48 (53%) set no upper age limit and 18 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Renal Insufficiency by Novartis, or all of them as a file.
02

Study summary

The purpose of this study is to characterize the pharmacokinetics (PK) and safety profile of asciminib following a single oral dose in adult subjects with renal impairment compared to a matched group of healthy subjects with normal renal function.

The results will determine whether or not a dose adjustment should be recommended when treating patients with asciminib who have impaired renal function.

03

Conditions studied

  • Renal Impairment

Browse trials for

Keywords

  • ABL001
  • asciminib
  • impaired renal function
  • pharmacokinetics
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or sterile / female
  • between 18 and 36 kg/m2, body weight greater than or equal to 50 kg and no more than 120 kg
  • Adequate venous access for blood sampling
  • For healthy volunteers: subject must be matched to at least one renal impaired subject by age (+/- 10 years), body weight (+/- 20%) and gender
  • For renal impaired subjects: documented stable renal disease without evidence of progressive decline in renal function (stable renal disease is defined as no significant change, such as, stable aGFR \< 90, for 12 weeks prior to study entry)

Exclusion criteria

Exclusion Criteria:

  • women of / pregnant / nursing
  • or to any drug or metabolites from similar class as asciminib or to any of the study drug
  • cardiac or cardiac repolarization abnormality
  • history of psychiatric illness within the past 2 years
  • history of acute or chronic pancreatitis
  • subject on dialysis
  • smokers (use of tobacco products in the previous 3 months) and not willing to abstain from using tobacco during the study
  • any surgical or medical condition altering the absorption, distribution, metabolism or excretion of drug
  • history of immunodeficiency diseases, including a positive (HIV) test result at screening
  • chronic infection with virus (HBV) or virus (HCV) at screening
  • donation or loss of 400 mL or more of blood or plasma within 8 weeks prior to dosing or other amount considered to compromise the health of the subject if previous history of anemia exists
  • use of the following drugs within 28 days prior to dosing: drugs that prolong the ; inhibitors and inducers; BCRP, UGT and PgP inhibitors and inducers

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Normal renal function

    healthy volunteers with normal renal function

    Drug: Asciminib

  • Experimental
    Severe renal impairment

    subjects with severe renal impairment

    Drug: Asciminib

  • Experimental
    Moderate renal impairment

    subject with moderate renal impairment

    Drug: Asciminib

  • Experimental
    Mild renal impairment

    subjects with mild renal impairment

    Drug: Asciminib

Interventions

  • 40 mg single dose

    Also known as: ABL001

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics: Plasma concentration of asciminib by AUClast

    The AUC from time zero to the last measurable concentration sampling time (tlast) (ng\*h/mL)

    Time frame: pre-dose (0 hour) and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48 and 72 hours post-dose

  2. Pharmacokinetics: Plasma concentration of asciminib by AUCinf

    The AUC from time zero to infinity (ng\*h/mL)

    Time frame: pre-dose (0 hour) and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48 and 72 hours post-dose

  3. Pharmacokinetics: Plasma concentration of asciminib by Cmax

    The maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration (ng/mL)

    Time frame: pre-dose (0 hour) and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48 and 72 hours post-dose

  4. Pharmacokinetics: Clearance of asciminib from plasma by CL/F

    The total body clearance of drug from the plasma (L/h)

    Time frame: pre-dose (0 hour) and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48 and 72 hours post-dose

Secondary outcomes

  1. Asciminib PK parameters unbound AUClast (AUClast)u and unbound AUCinf (AUCinf)u based on unbound fraction in plasma

    including but not limited to: (AUClast)u: area under the unbound plasma concentration-time curve calculated to the last quantifiable concentration point (ng\*h/mL)), - (AUCinf)u: unbound plasma concentration-time curve extrapolated to infinity. It is calculated as AUCinf ,u= AUClast ,u+ Clast,u/Lambda_z. (ng\*h/mL)

    Time frame: pre-dose (0 hour) and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48 and 72 hours post-dose

  2. Asciminib PK parameters unbound Cmax (Cmax)u based on unbound fraction in plasma

    The observed maximum unbound plasma concentration following administration (ng/mL)

    Time frame: pre-dose (0 hour) and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48 and 72 hours post-dose

  3. Asciminib secondary PK parameters Tmax, T1/2

    including but not limited to: * Tmax: the time to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration after single dose administration (h) * T1/2: the elimination half-life associated with the terminal slope (lz) of a semi logarithmic concentration-time curve (h).

    Time frame: pre-dose (0 hour) and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48 and 72 hours post-dose

  4. Asciminib secondary PK parameter AUC0-72h

    The area under the unbound plasma concentration-time curve from time zero to 72 h post-dosing (ng\*h/mL)

    Time frame: pre-dose (0 hour) and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48 and 72 hours post-dose

  5. Asciminib secondary PK parameters Vz/F

    apparent unbound drug volume of distribution during the terminal elimination phase following extravascular administration

    Time frame: pre-dose (0 hour) and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48 and 72 hours post-dose

  6. Percentage of participants with plasma protein binding as expressed by unbound fraction in plasma

    asciminib plasma protein binding in subjects with impaired renal function and subjects with normal renal function

    Time frame: 2 hours post-dose

07

Study locations

2 sites
  • Novartis Investigative Site
    Sofia, 1612, Bulgaria
  • Novartis Investigative Site
    Berlin, 14050, Germany
08

References and documents

Publications

  • Hoch M, Sato M, Zack J, Quinlan M, Sengupta T, Allepuz A, Aimone P, Hourcade-Potelleret F. Pharmacokinetics of Asciminib in Individuals With Hepatic or Renal Impairment. J Clin Pharmacol. 2021 Nov;61(11):1454-1465. doi: 10.1002/jcph.1926. Epub 2021 Jul 16. PubMed 34115385 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Mar 2019, 4 months.

Of 212 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 4 months is below that.

Counting every sponsor, half of 230 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2018
First posted
Jul 30, 2018
StartActual
Nov 16, 2018
Primary completionActual
Mar 18, 2019
CompletionActual
Apr 14, 2019
Last update
Oct 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03605277
Responsible party
Sponsor
First posted
Jul 30, 2018
Start date
Nov 16, 2018
Primary completion
Mar 18, 2019
Completion
Apr 14, 2019
Last update
Oct 12, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Asciminib

Start the discussion